Latest Period
Q2 2026
Security Snapshot
NovoCure Ltd - Ordinary Shares, no par value per share (NVCR) Institutional Ownership
CUSIP: G6674U108
13F Institutional Holders and Ownership History from Q4 2015 to Q2 2026
Institutions Reporting
214
Shares (Excl. Options)
103,345,355
Price
$15.15
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, no par value per share
- Symbol
- NVCR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 103,345,355
- Total 13F value
- $1,566,090,952
- Portfolio coverage rank
- 0%
- Share change
- +4,397,597
- Value change
- +$75,568,598
- Number of holders
- 214
- Shares outstanding
- 115,301,000
- SEC-reported price per share
- $16.03
- Insider filing price
- $16.03
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NVCR - NovoCure Ltd - Ordinary Shares, no par value per share is tracked under CUSIP G6674U108.
- 214 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 223 to 214 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,076,876,627 to $1,566,090,952.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 214 institutions filings for Q2 2026.
Security key
G6674U108
Latest holder period
Q2 2026
13F holders
214
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
NVCR full holder history
NovoCure Ltd SEC filings
NovoCure Ltd company facts
NovoCure Ltd insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G6674U108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
NVCR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 9.1% | +19% | $110,694,725 | +$20,696,209 | 10,492,391 | +23% | Soleus Capital Master Fund, L.P. | 31 Mar 2026 |
| BlackRock, Inc. | 8.3% | $168,501,151 | 9,083,620 | BlackRock, Inc. | 31 Mar 2025 | |||
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.6% | $69,105,935 | 6,339,994 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| Capital World Investors | 1.8% | -65% | $25,840,000 | -$56,626,396 | 2,000,000 | -69% | Capital World Investors | 30 Sep 2025 |
As of 30 Jun 2026, 214 institutional investors reported holding 103,345,355 shares of NovoCure Ltd - Ordinary Shares, no par value per share (NVCR). This represents 90% of the company’s total 115,301,000 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
73%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 17,373,078 | +1.8% | 0.01% | $263,202,136 |
| BlackRock, Inc. | 12% | 13,413,699 | +1.7% | 0% | $203,217,541 |
| Soleus Capital Management, L.P. | 8.6% | 9,913,401 | -5.5% | 5.2% | $150,188,025 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.4% | 6,272,490 | +0.33% | 0% | $95,028,224 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 4,903,633 | +4.7% | 0% | $74,290,040 |
| MORGAN STANLEY | 3.9% | 4,522,388 | -0.42% | 0% | $68,514,192 |
| STATE STREET CORP | 2.5% | 2,866,546 | +12% | 0% | $43,428,172 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 2,798,351 | +11% | 0% | $42,403,068 |
| WELLS FARGO & COMPANY/MN | 2.2% | 2,528,093 | -14% | 0.01% | $38,300,608 |
| Quantinno Capital Management LP | 1.9% | 2,223,455 | -11% | 0.04% | $33,685,343 |
| RENAISSANCE TECHNOLOGIES LLC | 1.7% | 1,951,911 | +26% | 0.04% | $29,571,452 |
| JPMORGAN CHASE & CO | 1.4% | 1,671,082 | +80% | 0% | $25,943,489 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1.2% | 1,385,600 | +91% | 0.03% | $20,991,840 |
| Palo Alto Investors LP | 1.1% | 1,280,439 | 0% | 2.8% | $19,398,651 |
| Nuveen, LLC | 1.1% | 1,232,087 | +25% | 0% | $18,666,119 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 1% | 1,164,072 | -13% | 0.06% | $17,635,691 |
| Empowered Funds, LLC | 1% | 1,154,431 | 0.09% | $17,489,630 | |
| AQR CAPITAL MANAGEMENT LLC | 0.96% | 1,102,131 | +301% | 0.01% | $16,653,200 |
| DIMENSIONAL FUND ADVISORS LP | 0.95% | 1,091,946 | +14% | 0% | $16,545,362 |
| D. E. Shaw & Co., Inc. | 0.89% | 1,022,480 | +58% | 0.01% | $15,490,572 |
| NORTHERN TRUST CORP | 0.84% | 973,202 | +10% | 0% | $14,744,011 |
| C WorldWide Group Holding A/S | 0.84% | 971,784 | 0% | 0.36% | $14,723,000 |
| GOLDMAN SACHS GROUP INC | 0.84% | 963,917 | +29% | 0% | $14,603,350 |
| BAILLIE GIFFORD & CO | 0.83% | 952,074 | -11% | 0.01% | $14,423,921 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 0.81% | 928,740 | +18% | 0.09% | $14,070,411 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
43
Latest
Q2 2026
Rows shown
1-25 of 43
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 103,345,355 | $1,566,090,952 | +$75,568,598 | $15.15 | 214 |
| 2026 Q1 | 98,879,062 | $1,076,876,627 | +$17,872,198 | $10.90 | 223 |
| 2025 Q4 | 95,517,696 | $1,235,387,380 | +$57,867,188 | $12.93 | 239 |
| 2025 Q3 | 91,721,734 | $1,185,106,020 | -$66,176,848 | $12.92 | 242 |
| 2025 Q2 | 94,465,807 | $1,681,500,579 | -$12,863,892 | $17.80 | 238 |
| 2025 Q1 | 95,188,552 | $1,696,317,176 | +$20,032,618 | $17.82 | 224 |
| 2024 Q4 | 91,572,450 | $2,728,943,845 | -$6,464,722 | $29.80 | 236 |
| 2024 Q3 | 92,870,663 | $1,451,669,038 | -$11,191,370 | $15.63 | 220 |
| 2024 Q2 | 92,908,941 | $1,591,540,722 | +$79,622,550 | $17.13 | 229 |
| 2024 Q1 | 89,139,144 | $1,393,246,216 | -$17,794,761 | $15.63 | 231 |
| 2023 Q4 | 90,513,054 | $1,351,320,799 | -$31,137,056 | $14.93 | 213 |
| 2023 Q3 | 92,292,343 | $1,490,614,876 | -$68,391,278 | $16.15 | 219 |
| 2023 Q2 | 90,419,824 | $3,752,040,945 | +$42,388,515 | $41.50 | 255 |
| 2023 Q1 | 89,476,517 | $5,380,865,921 | +$285,351,944 | $60.14 | 291 |
| 2022 Q4 | 84,791,322 | $6,218,802,349 | -$14,733,916 | $73.35 | 292 |
| 2022 Q3 | 83,680,222 | $6,357,718,291 | +$227,343,238 | $75.98 | 291 |
| 2022 Q2 | 80,381,456 | $5,588,033,518 | -$44,506,350 | $69.50 | 291 |
| 2022 Q1 | 81,277,607 | $6,732,621,045 | +$216,637,732 | $82.85 | 293 |
| 2021 Q4 | 79,039,910 | $5,935,576,060 | +$45,870,200 | $75.08 | 292 |
| 2021 Q3 | 77,530,211 | $9,007,824,387 | -$79,435,404 | $116.17 | 301 |
| 2021 Q2 | 77,621,320 | $17,214,766,292 | +$574,320,737 | $221.82 | 351 |
| 2021 Q1 | 75,251,763 | $9,945,540,551 | +$137,940,262 | $132.18 | 315 |
| 2020 Q4 | 74,207,296 | $12,840,473,582 | +$248,693,042 | $173.04 | 348 |
| 2020 Q3 | 73,245,441 | $8,150,888,382 | +$548,147,986 | $111.31 | 272 |
| 2020 Q2 | 69,147,487 | $4,099,622,932 | -$81,841,604 | $59.30 | 257 |